GLP-1 Medications: What They Are and Why They Matter

GLP-1 medications are drugs that copy a gut hormone called GLP-1, which your body releases after you eat. They lower blood sugar, slow digestion and quiet hunger signals in the brain. The best-known ones are Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide), and in 2026 the class also includes daily pills like Ozempic tablets, the Wegovy pill and Foundayo.

They started as diabetes drugs, became the most effective weight-loss medicines ever approved, and now have proven benefits for the heart, kidneys and sleep apnea. They're also expensive, often uncomfortable at first, and they work only while you take them. Here's the plain-English version of what they are and why they matter.

GLP-1 stands for glucagon-like peptide-1. Cells in your intestine release it when food arrives, and it sends several signals at once: tell the pancreas to release insulin if blood sugar is rising, tell it to release less glucagon (the hormone that raises blood sugar), slow down how fast the stomach empties, and tell the brain you've had enough.

Your own GLP-1 is broken down within a couple of minutes, so its effect is brief. GLP-1 medications are engineered to resist that breakdown and last much longer, a full week in the case of the weekly shots. That steady signal is what makes them so much stronger than anything your gut produces on its own. For a deeper look at the hormone itself, see What Is GLP-1?.

One detail explains why these drugs rarely cause low blood sugar on their own: the insulin boost only happens when blood sugar is elevated. The risk of lows mainly comes from combining them with insulin or sulfonylureas.

Most people know two or three names. Here's the full U.S. lineup that matters as of October 2026, grouped by what they're approved for. Several are the same molecule sold under different brands for different uses.

Two things in that table trip people up. First, tirzepatide isn't a pure GLP-1 drug; it also activates a second hormone receptor (GIP), which is part of why it produces more weight loss. Second, Foundayo isn't a peptide at all. It's a small molecule that switches on the same receptor, which is why it can be taken as a pill without the empty-stomach rules that oral semaglutide needs.

Before GLP-1 drugs, most diabetes medicines lowered blood sugar but did little else, and several caused weight gain. GLP-1 drugs lower A1C substantially while helping people lose weight, and they rarely cause dangerous lows on their own.

The bigger shift came from outcome trials. In SUSTAIN-6, semaglutide cut major cardiovascular events (heart attack, stroke or cardiovascular death) by 26% in people with type 2 diabetes and high heart risk. In FLOW, it lowered the risk of serious kidney outcomes by 24% in people with diabetes and kidney disease. That's why current diabetes guidelines often recommend a GLP-1 drug early for people with heart or kidney disease, not just as a last resort.

Older weight-loss drugs typically produced 5% to 10% weight loss at best. Semaglutide 2.4 mg (Wegovy) produced about 15% in its main trial, and tirzepatide about 20%. In SURMOUNT-5, the first head-to-head trial in obesity, tirzepatide led to 20.2% average weight loss versus 13.7% for semaglutide after 72 weeks.

The more lasting change may be in how obesity is understood. When a drug that changes appetite signals produces this much weight loss, it's hard to keep framing body weight as purely a matter of willpower. In the SELECT trial, Wegovy also lowered major cardiovascular events by 20% in people with obesity and heart disease but without diabetes, which made the case that treating obesity medically protects health, not just appearance.

The list of approved uses has grown quickly, and research is still expanding it.

GLP-1 drugs aren't easy for everyone. Nausea, vomiting, diarrhea and constipation are common, especially in the first weeks and after each dose increase, which is why doses start low and rise slowly. Rarer but serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration, and people with a personal or family history of medullary thyroid cancer shouldn't take them. Our Is Ozempic Safe? guide covers the full safety picture.

Some of the weight lost is muscle, so protein and strength training matter. And the drugs work only while you take them: when people stop, appetite returns and weight often comes back. That makes them closer to blood pressure medicine than to a one-time fix. See what happens when you stop.

Then there's cost. Insurance often covers GLP-1s for diabetes but not for weight loss, though self-pay prices have dropped sharply in 2026, with some pills starting at $149 a month. Our alternatives guide compares current prices.

The popularity of these drugs created a market for things that borrow the name. Supplements, teas, patches and drops marketed as "GLP-1 boosters" or "nature's Ozempic" don't come close to the effect of prescription drugs, and there's no FDA-approved GLP-1 patch. Fiber, protein and some foods can nudge your own GLP-1 release a little, which is fine, but it's not comparable to a medicine engineered to last a week.

More dangerous are products sold as real GLP-1 drugs without a prescription: "research" vials, counterfeit pens, and drugs that aren't approved at all, like retatrutide. FDA has warned about all of them. Our compounded semaglutide guide explains how to tell legitimate products from risky ones.

GLP-1 medications mimic a natural gut hormone, but in a much stronger and longer-lasting form. They've changed diabetes care, made obesity treatable with medicine in a way that wasn't possible before, and shown real benefits for the heart, kidneys, liver and sleep apnea. They also come with side effects, cost and the reality that results last only as long as treatment does. Used well, with a prescriber who knows the class, they're one of the most important medical advances of the past decade.